Experts discussed how NALIRIFOX compares with FOLFIRINOX and gemcitabine/nab-paclitaxel as frontline therapy for metastatic pancreatic cancer.
Navigating First-Line Treatment in Metastatic Pancreatic Adenocarcinoma
Experts discussed proactive strategies for managing diarrhea and making dose reduction decisions with NALIRIFOX in pancreatic cancer.
Experts compared outcomes for NALIRIFOX in patients with metastatic pancreatic cancer based on real-world and clinical trial data.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Tucatinib Combo as Maintenance in HER2+ Breast Cancer
2
Selinexor-Based Quadruplet Targets Myeloma After T-Cell Redirecting Therapy
3
Firmonertinib Misses PFS End Point in First-Line EGFR Exon 20 NSCLC
4
Personalized Vaccines May Have Utility Across All Lung Cancer Stages
5